Deryk T. LOO,Juniper A. SCRIBNER,Bhaswati BARAT,Leslie, S. JOHNSON,Ezio BONVINI,Gundo DIEDRICH
申请号：
MX2019007404
公开号：
MX2019007404A
申请日:
2017.12.21
申请国别(地区):
MX
年份:
2019
代理人:
摘要：
The present invention is directed to molecules, such as monospecific antibodies and bispecific, trispecific or multispecific binding molecules, including diabodies, BiTEs, and antibodies that are capable of specifically binding to "Disintegrin and Metalloproteinase Domain-containing Protein 9" ("ADAM9"). The invention particularly concerns such binding molecules that are capable of exhibiting high affinity binding to human and non- human ADAM9. The invention further particularly relates to such molecules that are thereby cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such ADAM9-binding molecules that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such ADAM9-binding molecule to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such ADAM9-binding molecules, and to methods involving the use of any of such ADAM9-binding molecules in the treatment of cancer and other diseases and conditions.La presente invención se dirige a moléculas, tales como anticuerpos monoespecíficos y moléculas de unión biespecíficas, triespecíficas o multiespecíficas, incluyendo anticuerpos, BiTEs y anticuerpos que son capaces de unirse específicamente a la "Proteína 9 que contiene Dominio de Desintegrina y Metaloproteinasa" ("ADAM9"). La invención particularmente se refiere a tales moléculas de unión que son capaces de mostrar unión de alta afinidad a ADAM9 humana y no humana. La invención además se relaciona particularmente con tales moléculas que de este modo son de reacción cruzada con ADAM9 humana y la ADAM9 de un primate no humano (por ejemplo, un mono cynomolgus). La invención adicionalmente pertenece a todas las moléculas de unión a ADAM9 que comprenden un Dominio variable de cadena ligera (VL) y/o un
